ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Arrakis raises $75 million series B for RNA-targeting small molecules

by Ryan Cross
April 20, 2019 | APPEARED IN VOLUME 97, ISSUE 16

 

Arrakis Therapeutics has raised $75 million in series B financing to advance its pipeline of small-molecule drugs that target RNA. The start-up has spent the past 2 years building a platform to screen compound libraries against RNA molecules that encode proteins considered undruggable. One of those proteins is a cancer-connected transcription factor called Myc. Arrakis has found molecules that may be able to prevent transcription of Myc messenger RNA, thereby lowering levels of the protein.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment